U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The initiative is part of the department’s broader “Making America Healthy Again” (MAHA) agenda.
Speaking before the House Energy and Commerce Committee’s Health Subcommittee, Kennedy emphasized the importance of personal health data. “My vision is that every American is wearing a wearable within four years,” he said. “It’s a way for people to take control of their health—seeing real-time impacts of food on glucose levels and heart rate.”
The announcement boosted shares of glucose-monitoring device makers. Dexcom (NASDAQ:DXCM) surged 10%, while Abbott gained 3.6% in afternoon trading.
Kennedy, a longtime advocate for preventive health and a critic of overreliance on pharmaceuticals, pointed to the cost-effectiveness of wearables compared to popular weight-loss drugs. “Ozempic costs $1,300 a month. If you can achieve similar results with an $80 wearable, that’s a better deal for Americans,” he noted. While he has criticized drugs like Novo Nordisk’s Ozempic, Kennedy supports their use for patients with morbid obesity or diabetes, when combined with exercise.
The campaign, which he described as one of the largest in HHS history, aims to shift the focus from reactive to proactive health management. Kennedy also hinted at exploring ways to subsidize wearables to make them more accessible.
J.P. Morgan analyst Robbie Marcus cautioned against assuming immediate changes in Medicare or insurance coverage for proactive monitoring, saying it’s too early to predict policy shifts.
The wearable tech market stands to benefit from this government push, as health monitoring tools become more mainstream in personal wellness strategies.


Abbas Reaffirms November 28 Palestinian Elections
Kremlin Says No Decision Yet on Putin-Trump December Summit
Ghana Says Western Support Growing for Slave Trade Reparations
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
France Keeps Top Health Alert as Officials Brace for Another Heatwave
US Senate Rejects Iran War Powers Resolution in 50-49 Vote
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks
North Korea Warns South Korea Over US-Led Defense Role
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Trump Asks Supreme Court to Restore Third-Country Deportations
Saudi Arabia, Turkey and Pakistan Plan Urgent Defence Talks Over Houthi Attacks
Trump Signs Order to Cut Routine Childhood Vaccines
Russian Missile and Drone Attack on Kyiv Kills Two, Damages Maternity Hospital
Netanyahu Defends Israel at UN as Delegates Stage Walkout
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 



